Skip to main content
Erschienen in: Tumor Biology 6/2015

01.06.2015 | Research Article

Relation of glypican-3 and E-cadherin expressions to clinicopathological features and prognosis of mucinous and non-mucinous colorectal adenocarcinoma

verfasst von: Abd Al-Rahman Mohammad Foda, Mie Ali Mohammad, Azza Abdel-Aziz, Amira Kamal El-Hawary

Erschienen in: Tumor Biology | Ausgabe 6/2015

Einloggen, um Zugang zu erhalten

Abstract

Glypican-3 (GPC3) is a member of the membrane-bound heparin sulfate proteoglycans. E-cadherin is an adhesive receptor that is believed to act as a tumor suppressor gene. Many studies had investigated E-cadherin expressions in colorectal carcinoma (CRC) while only one study had investigated GPC3 expression in CRC. This study aims to investigate expression of GCP3 and E-cadherin in colorectal mucinous carcinoma (MA) and non-mucinous adenocarcinoma (NMA) using manual tissue microarray technique. Tumor tissue specimens are collected from 75 cases of MC and 75 cases of NMA who underwent radical surgery from Jan 2007 to Jan 2012 at the Gastroenterology Centre, Mansoura University, Egypt. Their clinicopathological parameters and survival data were revised and analyzed using established statistical methodologies. High-density manual tissue microarrays were constructed using modified mechanical pencil tip technique and immunohistochemistry for GPC3 and E-cadherin was done. NMA showed higher expression of GPC3 than MA with no statistically significant relation. NMA showed a significantly higher E-cadherin expression than MA. GPC3 and E-cadherin positivity rates were significantly interrelated in NMA, but not in MA, group. In NMA group, there was no significant relation between either GPC3 or E-cadherin expression and the clinicopathological features. In a univariate analysis, neither GPC3 nor E-cadherin expression showed a significant impact on disease-free survival (DFS) or overall survival (OS). GPC3 and E-cadherin expressions are not independent prognostic factors in CRC. However, expressions of both are significantly interrelated in NMA patients, suggesting an excellent interplay between both, in contrast to MA. Further molecular studies are needed to further explore the relationship between GCP3 and E-cadherin in colorectal carcinogenesis.
Literatur
1.
Zurück zum Zitat Fenoglio-Preiser CM, Noffsinger AE, Stemmermann GN (2008) Epithelial neoplasms of the colon—adenocarcinoma. In: Fenoglio-Preiser CM, Noffsinger AE, Stemmermann GN, editor. Gastrointestinal Pathology: An Atlas and Text, 3rd Edn. Lippincott Williams & Wilkins, pp 955-1016 Fenoglio-Preiser CM, Noffsinger AE, Stemmermann GN (2008) Epithelial neoplasms of the colon—adenocarcinoma. In: Fenoglio-Preiser CM, Noffsinger AE, Stemmermann GN, editor. Gastrointestinal Pathology: An Atlas and Text, 3rd Edn. Lippincott Williams & Wilkins, pp 955-1016
2.
Zurück zum Zitat Hamilton SR, Bosman FT, Boffetta P, et al. Tumors of the colon and rectum. In: Bosman FT, Carneiro F, Hruban RH, et al., editors. WHO Classification Of Tumors Of The Digestive System. Lyon: IARCPress; 2010. p. 132–82. Hamilton SR, Bosman FT, Boffetta P, et al. Tumors of the colon and rectum. In: Bosman FT, Carneiro F, Hruban RH, et al., editors. WHO Classification Of Tumors Of The Digestive System. Lyon: IARCPress; 2010. p. 132–82.
3.
Zurück zum Zitat Mekenkamp JM, Heesterbeek KJ, Koopman M, et al. Mucinous adenocarcinomas: Poor prognosis in metastatic colorectal cancer. Eur J Cancer. 2012;48:501–9.CrossRefPubMed Mekenkamp JM, Heesterbeek KJ, Koopman M, et al. Mucinous adenocarcinomas: Poor prognosis in metastatic colorectal cancer. Eur J Cancer. 2012;48:501–9.CrossRefPubMed
4.
Zurück zum Zitat Yamaguchi T, Taniguchi H, Fujita S, Sekine S, Yamamoto S, Akasu T, et al. Clinicopathological characteristics and prognostic factors of advanced colorectal mucinous adenocarcinoma. Histopathology. 2012;61:162–9.CrossRefPubMed Yamaguchi T, Taniguchi H, Fujita S, Sekine S, Yamamoto S, Akasu T, et al. Clinicopathological characteristics and prognostic factors of advanced colorectal mucinous adenocarcinoma. Histopathology. 2012;61:162–9.CrossRefPubMed
5.
Zurück zum Zitat Foda AA, El-Hawary AK, Abdel-Aziz A. Differential expression of matrix metalloproteinase-13 in mucinous and nonmucinous colorectal carcinomas. Ann Diagn Pathol. 2013;17(4):347–51.CrossRefPubMed Foda AA, El-Hawary AK, Abdel-Aziz A. Differential expression of matrix metalloproteinase-13 in mucinous and nonmucinous colorectal carcinomas. Ann Diagn Pathol. 2013;17(4):347–51.CrossRefPubMed
6.
Zurück zum Zitat Foda AA, El-Hawary AK, Abdel Aziz A, Hosni A, Zalata KR, Gado AI. Rare Mucinous colorectal adenocarcinoma: analysis of the epidemiological factors in relation to survival in Egyptian patients. Am J Cancer Epidemiol Prev. 2014;2(1):10–9. Foda AA, El-Hawary AK, Abdel Aziz A, Hosni A, Zalata KR, Gado AI. Rare Mucinous colorectal adenocarcinoma: analysis of the epidemiological factors in relation to survival in Egyptian patients. Am J Cancer Epidemiol Prev. 2014;2(1):10–9.
7.
Zurück zum Zitat Shirakawa H, Suzuki H, Shimomura M, et al. Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma. Cancer Sci. 2009;100:1403–7.CrossRefPubMed Shirakawa H, Suzuki H, Shimomura M, et al. Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma. Cancer Sci. 2009;100:1403–7.CrossRefPubMed
8.
Zurück zum Zitat Kandil DH, Cooper K. GPC-3: a novel diagnostic marker for hepatocellular carcinoma and more. Adv Anat Pathol. 2009;16:125–9.CrossRefPubMed Kandil DH, Cooper K. GPC-3: a novel diagnostic marker for hepatocellular carcinoma and more. Adv Anat Pathol. 2009;16:125–9.CrossRefPubMed
9.
Zurück zum Zitat Shafizadeh N, Ferrell LD, Kakar S. Utility and limitations of GPC-3 expression for the diagnosis of hepatocellular carcinoma at both ends of the differentiation spectrum. Mod Pathol. 2008;21:1011–8.CrossRefPubMed Shafizadeh N, Ferrell LD, Kakar S. Utility and limitations of GPC-3 expression for the diagnosis of hepatocellular carcinoma at both ends of the differentiation spectrum. Mod Pathol. 2008;21:1011–8.CrossRefPubMed
11.
Zurück zum Zitat Aviel-Ronen S, Lau SK, Pintilie M, et al. GPC-3 is overexpressed in lung squamous cell carcinoma, but not in adenocarcinoma. Mod Pathol. 2008;21:817–25.CrossRefPubMed Aviel-Ronen S, Lau SK, Pintilie M, et al. GPC-3 is overexpressed in lung squamous cell carcinoma, but not in adenocarcinoma. Mod Pathol. 2008;21:817–25.CrossRefPubMed
12.
13.
Zurück zum Zitat Gavard J, Gutkind JS. A Molecular Crosstalk between E-cadherin and EGFR signaling networks. In: Haley JD, Gullick WJ, editors. Cancer drug discovery and development: EGFR signaling networks in cancer therapy 2nd edn. Humana Press: Springer Science; 2008. pp 139-154 Gavard J, Gutkind JS. A Molecular Crosstalk between E-cadherin and EGFR signaling networks. In: Haley JD, Gullick WJ, editors. Cancer drug discovery and development: EGFR signaling networks in cancer therapy 2nd edn. Humana Press: Springer Science; 2008. pp 139-154
14.
Zurück zum Zitat Capurro MI et al. GPC-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res. 2005;65(14):6245–54.CrossRefPubMed Capurro MI et al. GPC-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res. 2005;65(14):6245–54.CrossRefPubMed
15.
Zurück zum Zitat Huang JS et al. Diverse cellular transformation capability of overexpressed genes in human hepatocellular carcinoma. Biochem Biophys Res Commun. 2004;315(4):950–8.CrossRefPubMed Huang JS et al. Diverse cellular transformation capability of overexpressed genes in human hepatocellular carcinoma. Biochem Biophys Res Commun. 2004;315(4):950–8.CrossRefPubMed
16.
Zurück zum Zitat Rosivatz E, Becker I, Bamba M, Schott C, Diebold J, Mayr D, et al. Neoexpression of N-cadherin in E-cadherin-positive colon cancers. Int J Cancer. 2004;111:711–9.CrossRefPubMed Rosivatz E, Becker I, Bamba M, Schott C, Diebold J, Mayr D, et al. Neoexpression of N-cadherin in E-cadherin-positive colon cancers. Int J Cancer. 2004;111:711–9.CrossRefPubMed
17.
Zurück zum Zitat Elzagheid A, Algars A, Bendardaf R, et al. E-cadherin expression pattern in primary colorectal carcinomas and their metastases refl ects disease outcome. World J Gastroenterol. 2006;12:4304–9.CrossRefPubMedPubMedCentral Elzagheid A, Algars A, Bendardaf R, et al. E-cadherin expression pattern in primary colorectal carcinomas and their metastases refl ects disease outcome. World J Gastroenterol. 2006;12:4304–9.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Yuan DH, Xie HH, Wang Y, Meng CY, Yang LP, Feng YC, et al. Expression and significance of GPC-3 in colorectal cancer (Abs). Zhonghua Yi Xue Za Zhi. 2008;88(22):1540–2.PubMed Yuan DH, Xie HH, Wang Y, Meng CY, Yang LP, Feng YC, et al. Expression and significance of GPC-3 in colorectal cancer (Abs). Zhonghua Yi Xue Za Zhi. 2008;88(22):1540–2.PubMed
19.
Zurück zum Zitat Shebl AM, Zalata KR, Amin MM, et al. An inexpensive method of small paraffin tissue microarrays using mechanical pencil tips. Diagn Pathol. 2011;6:117–21.CrossRefPubMedPubMedCentral Shebl AM, Zalata KR, Amin MM, et al. An inexpensive method of small paraffin tissue microarrays using mechanical pencil tips. Diagn Pathol. 2011;6:117–21.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Foda AA. No-cost manual method for preparation of tissue microarrays having high quality comparable to semiautomated methods. Appl Immunohistochem Mol Morphol. 2013;21:271–4.PubMed Foda AA. No-cost manual method for preparation of tissue microarrays having high quality comparable to semiautomated methods. Appl Immunohistochem Mol Morphol. 2013;21:271–4.PubMed
22.
Zurück zum Zitat Khoursheed MA, Mathew TC, Makar RR, et al. Expression of E-cadherin in human colorectal cancer. Surg J R Coll Surg Edinb Irel. 2003;2:86–91. Khoursheed MA, Mathew TC, Makar RR, et al. Expression of E-cadherin in human colorectal cancer. Surg J R Coll Surg Edinb Irel. 2003;2:86–91.
23.
Zurück zum Zitat Hahn-stromberg V, Edvardsson H, Bodin L, et al. Disturbed expression of E-cadherin, beta-catenin and tight junction proteins in colon carcinoma is unrelated to growth pattern and genetic polymorphisms. APMIS. 2008;116:253–63.CrossRefPubMed Hahn-stromberg V, Edvardsson H, Bodin L, et al. Disturbed expression of E-cadherin, beta-catenin and tight junction proteins in colon carcinoma is unrelated to growth pattern and genetic polymorphisms. APMIS. 2008;116:253–63.CrossRefPubMed
24.
Zurück zum Zitat Jie D, Zhongmin Z, Guoqing L, et al. Positive expression of LSD1 and negative expression of e-cadherin correlate with metastasis and poor prognosis of colon cancer. Dig Dis Sci. 2013;58:1581–9.CrossRefPubMed Jie D, Zhongmin Z, Guoqing L, et al. Positive expression of LSD1 and negative expression of e-cadherin correlate with metastasis and poor prognosis of colon cancer. Dig Dis Sci. 2013;58:1581–9.CrossRefPubMed
25.
Zurück zum Zitat Tian X, Liu Z, Niu B, et al. E-cadherin/β-catenin complex and the epithelial barrier. J Biomed Biotechnol 2011:567305-567311. Tian X, Liu Z, Niu B, et al. E-cadherin/β-catenin complex and the epithelial barrier. J Biomed Biotechnol 2011:567305-567311.
26.
Zurück zum Zitat Yamauchi N, Watanabe A, Hishinuma M, Ohashi K, Midorikawa Y, et al. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol. 2005;18:1591–8. doi:10.1038/modpathol.3800436.PubMed Yamauchi N, Watanabe A, Hishinuma M, Ohashi K, Midorikawa Y, et al. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol. 2005;18:1591–8. doi:10.​1038/​modpathol.​3800436.PubMed
27.
Zurück zum Zitat Nakatsura T, Nishimura Y. Usefulness of the novel oncofetal antigen glypican-3 for diagnosis of hepatocellular carcinoma and melanoma. BioDrugs. 2005;19(2):71–7.CrossRefPubMed Nakatsura T, Nishimura Y. Usefulness of the novel oncofetal antigen glypican-3 for diagnosis of hepatocellular carcinoma and melanoma. BioDrugs. 2005;19(2):71–7.CrossRefPubMed
28.
Zurück zum Zitat Coggin Jr JH. The implications of embryonic gene expression in neoplasia. CRC Crit Rev Oncol Hematol. 1992;5:37–55.CrossRef Coggin Jr JH. The implications of embryonic gene expression in neoplasia. CRC Crit Rev Oncol Hematol. 1992;5:37–55.CrossRef
29.
Zurück zum Zitat Alshenawy HA, Ali MA. Differential caveolin-1 expression in colon carcinoma and its relation to E-cadherin–β-catenin complex. Ann Diagn Pathol. 2013;17(6):476–82.CrossRefPubMed Alshenawy HA, Ali MA. Differential caveolin-1 expression in colon carcinoma and its relation to E-cadherin–β-catenin complex. Ann Diagn Pathol. 2013;17(6):476–82.CrossRefPubMed
30.
Zurück zum Zitat Stanczak A, Stec R, Bodnar L, et al. Prognostic significance of Wnt-1, β-catenin and E-cadherin expression in advanced colorectal carcinoma. Pathol Oncol Res. 2011;17:955–63.CrossRefPubMedPubMedCentral Stanczak A, Stec R, Bodnar L, et al. Prognostic significance of Wnt-1, β-catenin and E-cadherin expression in advanced colorectal carcinoma. Pathol Oncol Res. 2011;17:955–63.CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Fang QX, Lu LZ, Yang B, et al. L1, b-catenin, and E-cadherin expression in patients with colorectal cancer: correlation with clinicopathologic features and its prognostic significance. J Surg Oncol. 2010;102:433–42.CrossRefPubMed Fang QX, Lu LZ, Yang B, et al. L1, b-catenin, and E-cadherin expression in patients with colorectal cancer: correlation with clinicopathologic features and its prognostic significance. J Surg Oncol. 2010;102:433–42.CrossRefPubMed
32.
Zurück zum Zitat Elzagheid A, Buhmeida A, Laato M, et al. Loss of E-cadherin expression predicts disease recurrence and shorter survival in colorectal carcinoma. APMIS. 2012;120:539–48.CrossRefPubMed Elzagheid A, Buhmeida A, Laato M, et al. Loss of E-cadherin expression predicts disease recurrence and shorter survival in colorectal carcinoma. APMIS. 2012;120:539–48.CrossRefPubMed
33.
Zurück zum Zitat El-Bahrawy MA, Poulsom R, Jeffery R, et al. The expression of E-cadherin and catenins in sporadic colorectal carcinoma. Hum Pathol. 2001;32:1216–24.CrossRefPubMed El-Bahrawy MA, Poulsom R, Jeffery R, et al. The expression of E-cadherin and catenins in sporadic colorectal carcinoma. Hum Pathol. 2001;32:1216–24.CrossRefPubMed
Metadaten
Titel
Relation of glypican-3 and E-cadherin expressions to clinicopathological features and prognosis of mucinous and non-mucinous colorectal adenocarcinoma
verfasst von
Abd Al-Rahman Mohammad Foda
Mie Ali Mohammad
Azza Abdel-Aziz
Amira Kamal El-Hawary
Publikationsdatum
01.06.2015
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 6/2015
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3115-x

Weitere Artikel der Ausgabe 6/2015

Tumor Biology 6/2015 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.